Stocktoria
NRX Pharmaceuticals, Inc. NRXP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-11-20
Chart by TradingView
4/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $1.2M | $0 | $0 | — | — |
| Operating income | -$16.2M | -$18.5M | -$27.8M | -$44.3M | -$115.8M |
| Net income | -$28.6M | -$25.1M | -$30.1M | -$39.8M | -$93.1M |
| Operating cash flow | -$14.1M | -$10.6M | -$21.7M | -$39.8M | -$37.7M |
| Total assets | $13.0M | $3.7M | $7.3M | $25.8M | $32.7M |
| Total liabilities | $28.9M | $26.9M | $19.0M | $18.4M | $11.9M |
| Shareholders' equity | -$15.9M | -$23.2M | -$11.7M | $7.4M | $20.8M |
| Ratios | |||||
| Operating margin | -1324.4% | — | — | — | — |
| Net margin | -2336.5% | — | — | — | — |
| Return on assets | -220.9% | -688.2% | -412.2% | -154.0% | -284.3% |
| Return on equity | 179.6% | 108.2% | 257.0% | -536.6% | -447.3% |
| Debt / equity | — | — | -0.78× | 0.38× | — |
| Current ratio | 0.31 | 0.15 | 0.36 | 1.66 | 2.74 |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001719406 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.